DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Christianson syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChristianson syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for christianson syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
solute carrier family 9 member A6 (SLC9A6) — SLC9A6 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9S0S · 3.4 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2019 study generated a mouse model carrying the NHE6 A9S variant, a human SLC9A6 variant that appears in control exome datasets. Male mice with the equivalent mutation showed normal brain size at 6 months, no cerebellar degeneration, no defective neuronal arborization, and no abnormality in intraendosomal pH compared with controls. These results contrast with findings in NHE6-null mice and indicate the A9S variant functions at a level equivalent to control NHE6 for the assays performed. The authors conclude the variant is unlikely to confer disease susceptibility with high penetrance.
A 2024 case report describes a 5-year-old boy with Christianson syndrome who presented with respiratory failure and progressive muscle weakness in all four extremities. He had acquired microcephaly, intellectual disability, global developmental delay, dysmorphic facial features, seizures, spastic tetraparesis, truncal hypotonia, speech impairment, failure to thrive, recurrent lung infections, self-mutilation, primary hyperparathyroidism, medullary nephrocalcinosis, and atlantoaxial instability due to os odontoideum. Brain MRI showed atlantoaxial instability, a narrow foramen magnum, myelopathy from spinal cord compression, and cerebral and cerebellar atrophy. The report notes this is the first documented case of atlantoaxial instability due to os odontoideum in Christianson syndrome and advises considering underlying myelopathy when muscle weakness increases.
A 2020 case report describes a 2.5-year-old boy diagnosed with refractory epilepsy with polymorphic seizures (tonic-clonic, myoclonic, atypical absence, and atonic seizures) starting at 15 months. The diagnosis was Christianson syndrome caused by a c.584+1 G>T SLC9A6 variant. The report lists the syndrome's features as specific facial and behavioural features, postnatal microcephaly, absent speech, truncal ataxia, and epilepsy.
No drug treatment or intervention is tested in any of these three reports. What is missing is any preclinical or clinical trial of a pharmacological agent for Christianson syndrome, any systematic study of seizure management in this population, and any investigation of whether the atlantoaxial instability described in one case is a common feature requiring routine screening.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
eNeuro · 2019 · 12 citations · open access
Functional Assessment<i>In Vivo</i>of the Mouse Homolog of the Human Ala-9-Ser NHE6 Variant
AbstractAbstract Christianson syndrome (CS) is an X-linked neurogenetic disorder resulting from loss-of-function (LoF) mutations in SLC9A6 , which encodes the endosomal Na + /H + exchanger 6 (NHE6). NHE6 regulates proton efflux from endosomes and, thus, participates in regulating cargo processing and trafficking. LoF mutations in NHE6 cause aberrant acidification of endosomes. While CS arises in males generally due to clear LoF mutations, other potentially hypomorphic variants have emerged, yet most of these variants have not been evaluated for functional effects, particularly in vivo . Here we characterize an SLC9A6 variant that has been previously reported in patients, yet now also appears in exome datasets of largely control individuals—c.25G>T, p.A9S. By heterologous expression in cell lines, we show that human NHE6A9S is expressed and localizes in a manner comparable to control NHE6. By genome editing, we generated the equivalent NHE6 mutation in mouse—p.A11S—and determined that male NHE6A11S mice have normal brain size at 6 months of age and do not show cerebellar degeneration or defective neuronal arborization. Neurons from male NHE6A11S mice also did not demonstrate an abnormality in intraendosomal pH compared with controls. These findings are in contrast to findings in NHE6-null mice previously reported and indicate that the NHE6A11S variant functions at a level equivalent to control NHE6 for many of the assays performed. These data stand in support of the population genetic data, which are also evaluated here, indicating that the A9S variant is unlikely to confer disease susceptibility with high penetrance.
Molecular Syndromology · 2024 · 0 citations · open access
Atlantoaxial Instability due to Os Odontoideum in a Child with Christianson Syndrome
AbstractIntroduction: gene located on the chromosome X. It is characterized by intellectual disability, developmental delay, speech and language impairments, dysmorphic features, seizures, ataxia, and neurobehavioral problems. Case Presentation: A 5-year-old boy was presented with respiratory failure and then progressive muscle weakness in all four extremities. He manifested acquired microcephaly, intellectual disability, global developmental delay, distinct dysmorphic facial features, seizures, spastic tetraparesis, truncal hypotonia, speech impairment, failure to thrive, malnutrition, recurrent lung infections, self-mutilation, primary hyperparathyroidism, medullary nephrocalcinosis, and atlantoaxial instability due to os odontoideum. Brain magnetic resonance imaging revealed atlantoaxial instability due to os odontoideum, a narrow foramen magnum, myelopathy due to spinal cord compression, and cerebral and cerebellar atrophy. Discussion: This report highlights a significant contribution by introducing a child with Christianson syndrome describing atlantoaxial instability due to os odontoideum, a previously undocumented phenomenon. This report suggests a potential link between Christianson syndrome and atlantoaxial instability. In children with Christianson syndrome experiencing increased muscle weakness in all extremities during follow-up, consideration of underlying myelopathy due to os odontoideum is advised.
American Journal of Biomedical Science & Research · 2020 · 0 citations · open access
Epilepsy in the X-linked Syndromic Intellectual Disability, Christianson Type Resulted from c.584+1 G>T SLC9A6 Variant
AbstractChristianson syndrome (CS) is an X-linked intellectual disorder caused by mutations in the SLC9A6 gene (Xq26 locus, XLD inheritance). It is characterized by specific facial and behavioral features, postnatal microcephaly, absent speech, truncal ataxia and epilepsy. We present a history of a 2, 5-year-old boy diagnosed with refractory epilepsy with polymorphic seizures (tonic-clonic, myoclonic, atypical absence and atonic seizures), diagnosed at the age of 15 months.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
